☰

James W. Antoon, Ph.D. - Publications

Affiliations: 
2010 Pharmacology Tulane University, New Orleans, LA, United States 
Area:
Pharmacology, Molecular Biology, Medicine and Surgery
Tree Info Grants Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Gestaut MM, Antoon JW, Burow ME, Beckman BS. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacological Reports : Pr. 66: 174-8. PMID 24905325 DOI: 10.1016/J.Pharep.2013.08.014  0.633
2014 Ponnapakam AP, Liu J, Bhinge KN, Drew BA, Wang TL, Antoon JW, Nguyen TT, Dupart PS, Wang Y, Zhao M, Liu YY, Foroozesh M, Beckman BS. 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. Bioorganic & Medicinal Chemistry. 22: 1412-20. PMID 24457089 DOI: 10.1016/J.Bmc.2013.12.065  0.688
2014 Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME. Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 53: 38-48. PMID 22911661 DOI: 10.1002/Mc.21946  0.604
2013 White MD, Chan L, Antoon JW, Beckman BS. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Research. 33: 3573-9. PMID 24023282  0.663
2013 Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, et al. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. Plos One. 8: e69291. PMID 23950888 DOI: 10.1371/Journal.Pone.0069291  0.746
2013 Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology. 42: 1139-50. PMID 23403951 DOI: 10.3892/Ijo.2013.1814  0.469
2012 Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Elliott S, McLachlan JA, Burow ME. Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. American Journal of Cancer Research. 2: 446-58. PMID 22860234  0.39
2012 Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Experimental Biology and Medicine (Maywood, N.J.). 237: 832-44. PMID 22859737 DOI: 10.1258/Ebm.2012.012028  0.751
2012 Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific Reports. 2: 539. PMID 22844580 DOI: 10.1038/Srep00539  0.699
2012 Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Burow ME. Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology & Therapy. 13: 1026-33. PMID 22825349 DOI: 10.4161/Cbt.20992  0.601
2012 Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. The Journal of Steroid Biochemistry and Molecular Biology. 132: 186-93. PMID 22634477 DOI: 10.1016/J.Jsbmb.2012.05.004  0.738
2012 Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, et al. Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. The Journal of Endocrinology. 214: 45-54. PMID 22562654 DOI: 10.1530/Joe-12-0097  0.641
2012 Antoon JW, White MD, Burow ME, Beckman BS. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncology Reports. 27: 1779-86. PMID 22469881 DOI: 10.3892/Or.2012.1743  0.723
2012 Antoon JW, Beckman BS. Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. Bioorganic & Medicinal Chemistry Letters. 22: 2624-8. PMID 22366655 DOI: 10.1016/J.Bmcl.2012.01.087  0.7
2012 Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS. Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Investigation. 30: 135-48. PMID 22250588 DOI: 10.3109/07357907.2011.636116  0.664
2011 Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer Journal of Molecular Endocrinology. 46: 205-216. PMID 21321095 DOI: 10.1530/Jme-10-0116  0.734
2011 Antoon JW, Beckman BS. Sphingosine kinase: a promising cancer therapeutic target. Cancer Biology & Therapy. 11: 647-50. PMID 21307640 DOI: 10.4161/Cbt.11.7.14921  0.625
2011 Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biology & Therapy. 11: 678-89. PMID 21307639 DOI: 10.4161/Cbt.11.7.14903  0.761
2010 Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Molecular Cancer. 9: 295. PMID 21087507 DOI: 10.1186/1476-4598-9-295  0.661
2010 Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 151: 5124-35. PMID 20861237 DOI: 10.1210/En.2010-0420  0.744
2010 Liu J, Antoon JW, Ponnapakkam A, Beckman BS, Foroozesh M. Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorganic & Medicinal Chemistry. 18: 5316-22. PMID 20639111 DOI: 10.1016/J.Bmc.2010.05.044  0.602
2010 Antoon JW, Liu J, Ponnapakkam AP, Gestaut MM, Foroozesh M, Beckman BS. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemotherapy and Pharmacology. 65: 1191-5. PMID 20155475 DOI: 10.1007/S00280-009-1233-0  0.724
2010 Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment. 121: 293-300. PMID 19597705 DOI: 10.1007/S10549-009-0458-2  0.665
2010 Antoon JW, White MD, Gestaut MM, Slaughter EM, Elliott S, Driver JL, Khalili HS, Smith CD, Burow ME, Beckman BS. Abstract 2537: The novel sphingosine kinase inhibitor ABC294640 blocks survival and tumorigenesis in chemo- And endocrine resistant breast cancer Cancer Research. 70: 2537-2537. DOI: 10.1158/1538-7445.Am10-2537  0.749
2010 White MD, Antoon JW, Meacham WD, Slaughter EM, Burow ME, Beckman BS. Abstract 1633: The sphingosine kinase inhibitor SKI-II blocks survival and MAPK signaling in human breast cancer in vitro Cancer Research. 70: 1633-1633. DOI: 10.1158/1538-7445.Am10-1633  0.741
2010 Gestaut MM, Antoon JW, Ponnapakam AP, J L, Burow ME, Foroozesh M, Beckman BS. Abstract 1031: Sphingolipid metabolism as a therapeutic target in chemotherapy resistant and hormone therapy resistant breast cancer Cancer Research. 70: 1031-1031. DOI: 10.1158/1538-7445.Am10-1031  0.721
2009 Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. Journal of Medicinal Chemistry. 52: 5748-52. PMID 19694470 DOI: 10.1021/Jm9009668  0.736
2009 Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS. Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Experimental Biology and Medicine (Maywood, N.J.). 234: 1253-63. PMID 19546354 DOI: 10.3181/0902-Mr-77  0.713
Show low-probability matches.